Generate Biomedicines, Inc. GENB
Generate Biomedicines, Inc. (Nasdaq: GENB) is a respiratory drug developer. Its lead program, GB-0895, is in Phase 3 for Severe asthma (long-acting anti-TSLP, Q26W dosing). Its next catalyst on record is GB-0895 (COPD): Phase 1b data readout (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: GB-0895 (COPD) — Phase 1b data readout (2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| GB-0895 | Severe asthma (SOLAIRIA-1 and SOLAIRIA-2) | antibody | Phase 3 |
| GB-0895 | Moderate-to-severe COPD (Phase 1b) | antibody | Phase 1 |
| GB-4362 | MMAE payload neutralizer adjunct to MMAE-ADCs (urothelial cancer combination with enfortumab vedotin plus pembrolizumab) | antibody | Phase 1 |
| GB-5267 | MUC16 armored CAR-T, platinum-resistant ovarian cancer (Roswell Park-sponsored Phase 1) | cell therapy | Pre-clinical |
| Next-generation ADC (internal) | Oncology | antibody | Pre-clinical |
| Amgen and Novartis collaboration programs (confidential) | — | protein/peptide | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 respiratory companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.